表纸
市场调查报告书

通用注射剂2020-产品,市场和参与者

Generic Injectables 2020 - Products, Markets and Players

出版商 Greystone Research Associates 商品编码 947987
出版日期 内容资讯 英文 160 Pages
商品交期: 最快1-2个工作天内
价格
通用注射剂2020-产品,市场和参与者 Generic Injectables 2020 - Products, Markets and Players
出版日期: 2020年07月07日内容资讯: 英文 160 Pages
简介

本报告分析了全球通用注射剂市场,并分析了市场的基本结构和背景(法规,经济学等),主要驱动因素/抑制因素,总体市场规模前景以及药品。我们将按类别,治疗类别,ANDA(缩写为新药申请)注册策略的趋势,专利竞争和诉讼状态以及市场影响收集详细信息。

内容

执行摘要

市场机会

  • 注射剂市场结构
  • 注塑市场增长趋势

仿制药:成长要因

  • 专利和排他性
  • 诉讼和先申请(FTF)下的ANDA策略
  • 买卖ANDA(新药批准申请的缩写)

通用注射产品注意事项

  • 提供的容器
  • 冻干/重组
  • 药物因素

仿制药市场分析

药物分类分析

  • 肾上腺素能激动剂
  • 助剂
  • 抗生素
  • 美学
  • 抗心律失常药
  • 抗凝剂
  • 抗惊厥药
  • 止吐药
  • 抗炎药
  • 降压药
  • 抗肿瘤药
  • 抗病毒药
  • 骨吸收抑制剂
  • 利尿剂
  • 叶酸代谢产物
  • 生长激素
  • 抑制剂
  • 肌肉松弛剂
  • 麻醉止痛药
  • 神经递质
  • 阿片类拮抗剂
  • 镇静剂
  • 血管扩张药

治疗类别分析

  • 循环器
  • 神经
  • 疼痛管理
  • 其他专业

市场因素

  • 法规问题
  • 诉讼问题
  • ANDA归档策略的发展
  • CMO(合同药品制造组织)的作用
  • 卫生经济学
目录

Tracking a Moving Target

The generic injectable drug segment is a rapidly evolving and highly unpredictable environment that lacks a true data compass to assist decision makers in mapping strategies for success in this segment. There are 248 distinct APIs for which there is at least one approved generic injectable ANDA. These 248 APIs account for 1,223 approved ANDAs. Including all approved doses, the current universe of generic injectables consists of 1,746 unique injectable products. These products are marketed and supplied by slightly less than one hundred companies.

Competition among the various drug and therapeutic classes is uneven, with the top ten segments accounting for a disproportionate level of activity and revenue. Understanding the underlying factors affecting business performance is key to attaining financial targets.

What You Will Learn:

  • Provides detailed analysis of generic drugs supplied as injectables and assesses key market segments, market dynamics and potential product opportunities
  • Presents the competitive picture for generic injectables in two dozen drug classes
  • Evaluates the importance of ANDA filing strategies and indirect ANDA acquisition on participant growth prospects
  • Analyzes the impact of patents, exclusivity and litigation on participant market sector prospects
  • Assesses the market presence and product position of the top twenty-four generic injectables suppliers
  • Evaluates the impact of economic, technology, and regulatory factors

Table of Contents

Executive Summary

The Market Opportunity

  • The Economics of Injectable Drugs
  • Growth in Injectables

Generic Injectables - Growth Factors

  • Patents and Exclusivity
  • Litigation and First-to-File ANDA Strategies
  • Buying and Selling ANDAs

Generic Injectables - Product Considerations

  • As-supplied Container
  • Lyophilization/Reconstitution
  • Formulation Factors

Generic Injectables Market Analysis

Drug Class Analysis

  • Adrenergic Agents
  • Anabolic Agents
  • Antibiotics
  • Anesthetics
  • Antiarrhythmics
  • Anticoagulants
  • Anticonvulsants
  • Antiemetics
  • Anti-inflammatory
  • Antihypertensives
  • Antineoplastics
  • Antivirals
  • Bone Resorption Inhibitors
  • Diuretics
  • Folic Acid Metabolites
  • Growth Hormone
  • Inhibitors
  • Muscle Relaxants
  • Narcotic Analgesics
  • Neurotransmitter
  • Opioid Antagonist
  • Sedatives
  • Vasodilators

Therapeutic Class Analysis

  • Cardiology
  • Hematology
  • Neurology
  • Pain Management
  • Other Key Classes

Market Factors

  • Regulatory Issues
  • Litigation Issues
  • Evolving ANDA Filing Strategies
  • The Role of CMOs
  • Healthcare Economics